Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-month, Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter-Phase 3 Trial to Evaluate the Safety and Efficacy of SMZ1 Tablet in Combination With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy

NCT07695207 is registered in ClinicalTrials.gov with SANGMYUNG innovation as lead sponsor.

NCT NCT07695207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07695207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-month, Randomization, Double-blind, Placebo-controlled, Parallel, Multicenter-Phase 3 Trial to Evaluate the Safety and Efficacy of SMZ1 Tablet in Combination With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Lead sponsor
SANGMYUNG innovation
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2025
Completion date
July 31, 2028
Enrollment
266 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular (wet) age-related macular degeneration without polypoidal choroidal vasculopathy